Pilot Study of Minocycline in Huntington's Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

November 30, 2008

Conditions
Huntington Disease
Interventions
DRUG

minocycline

Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)

DRUG

Matching placebo

Matching placebo 1 capsule twice daily, 18 months treatment duration.

Trial Locations (12)

Unknown

University of Alabama at Birmingham, Birmingham

Colorado Neurological Institute, Englewood

University of Florida, Gainesville

University of South Florida, Tampa

University of Maryland School of Medicine, Baltimore

Massachusetts General Hospital, Boston

Washington University School of Medicine, St Louis

Albany Medical College, Albany

Columbia University, New York

University of Rochester, Rochester

University of Texas Medical Branch at Galveston, Galveston

University of British Columbia, Vancouver

All Listed Sponsors
collaborator

FDA Office of Orphan Products Development

FED

lead

Merit Cudkowicz

NETWORK

NCT00277355 - Pilot Study of Minocycline in Huntington's Disease | Biotech Hunter | Biotech Hunter